from ymb only info i have re dostarlimab and LL
Post# of 148261
drD2 days agoReplied to a reaction
$CYDY conversation
@Jing
I can’t wait to read the MDA paper on checkpoint inhibitors ( dostarlimab) and Leronlimab synergy . This will be breakthrough designation . So it is possible that a BTD will be submitted using the combination of both these molecules after trials
.$CYDY conversation
@Hankster Yes . MDA is a powerhouse for cancer research .
I also guessed it would be MDA prior to Dr Kelly announcing it . But if you recall , Dr Kelly had been in talks with doctors at Sloan prior to that announcement … where was the dostarlimab study conducted at ? Sloan .
These are some of the diamonds we’ve been finding .
drD2 days agoReplied to a reaction
$CYDY conversation
@Jing I believe we have several potential partners one of them is definitely GSK . It doesn’t make sense for us to do a partnership for NASH first . The HIV BLA is compatible with their commitment to eradicate diseases that have plagued humanity and we are close to obtaining it .. “all hands on deck” . That’s why it appears this will be the first one . However , and coming shortly thereafter is the biggest one of them all cancer with a synergistic molecule owned by GSK !